Close Menu

NEW YORK (GenomeWeb) – Biocept announced today that it has signed agreements to sell $9.3 million in stock and warrants to certain institutional investors.

According to the company, it will sell about 4.3 million shares of its common stock at $2.15 per share, as well as warrants to purchase up to roughly 2.2 million shares of common stock at an exercise price of $2.50 a share. The warrants are exercisable six months after the close of the transaction and expire five years from the date they become exercisable.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.